Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Montelukast sodium
Necessity Supplies Ltd
R03DC03
Montelukast sodium
4mg
Chewable tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 03030200
PACKAGE LEAFLET: INFORMATION FOR THE USER SINGULAIR ® PAEDIATRIC 4 MG CHEWABLE TABLETS montelukast READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU GIVE THIS MEDICINE TO YOUR CHILD BECAUSE IT CONTAINS IMPORTANT INFORMATION. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for your child only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as your child’s. • If your child gets any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Singulair Paediatric is and what it is used for 2. What you need to know before your child takes Singulair Paediatric 3. How to take Singulair Paediatric 4. Possible side effects 5. How to store Singulair Paediatric 6. Contents of the pack and other information 1. WHAT SINGULAIR PAEDIATRIC IS AND WHAT IT IS USED FOR WHAT SINGULAIR PAEDIATRIC IS Singulair Paediatric is a leukotriene receptor antagonist that blocks substances called leukotrienes. HOW SINGULAIR PAEDIATRIC WORKS Leukotrienes cause narrowing and swelling of airways in the lungs. By blocking leukotrienes, Singulair Paediatric improves asthma symptoms and helps control asthma. WHEN SINGULAIR PAEDIATRIC SHOULD BE USED Your doctor has prescribed Singulair Paediatric to treat your child’s asthma, preventing asthma symptoms during the day and night. • Singulair Paediatric is used for the treatment of 2 to 5 year old patients who are not adequately controlled on their medication and need additional therapy. • Singulair Paediatric may also be used as an alternative treatment to inhaled corticosteroids for 2 to 5 year old patients who have not recently taken oral corticosteroids for their asthma and have shown that they are unable to use inhaled corticosteroids. • Singulair Paediatric also helps prevent the narrowing of airways triggered by exercise for patien Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Singulair Paediatric 4 mg chewable tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One chewable tablet contains montelukast sodium, which is equivalent to 4 mg montelukast. Excipients with known effect: This medicine contains 1.2 mg aspartame (E 951) per tablet. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Chewable tablet. Pink, oval, biconvex-shaped, size 10.9 mm x 7.8 mm with SINGULAIR engraved on one side and ‘MSD 711’ on the other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Singulair is indicated in the treatment of asthma as add-on therapy in those 2 to 5year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom “as-needed” short acting β -agonists provide inadequate clinical control of asthma. Singulair may also be an alternative treatment option to low-dose inhaled corticosteroids for 2 to 5 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.2). Singulair is also indicated in the prophylaxis of asthma from 2 years of age and older in which the predominant component is exercise-induced bronchoconstriction. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology This medicinal product is to be given to a child under adult supervision. For children who have problems consuming a chewable tablet, a granule formulation is available (see Singulair 4 mg granule SmPC). The recommended dose for paediatric patients 2-5 years of age is one 4 mg chewable tablet daily to be taken in the evening. If taken in connection with food, Singulair should be taken 1 hour before or 2 hours after food. No dosage adjustment within this age group is necessa Read the complete document